- PROFESSOR Medicine, Liver Diseases
American Board of Internal Medicine
- Colon Polypectomy
- Colon Polyps
- Esophageal Variceal Injection
- Esophageal Varices
- Flexible Sigmoidoscopy
- Gilbert's Syndrome
- HIV Coinfection in Viral Hepatitis
- Hepatitis A
- Hepatitis A Vaccine
- Hepatitis B
- Hepatitis B Vaccine
- Hepatitis C
- Liver Biopsy
- Toxic Hepatitis
- Upper GI Endoscopy
- Wilson's Disease
MD, New York University School of Medicine
NYU Medical Center
- Dr. Dieterich is currently Professor of Medicine in the Division of Liver Diseases and also Director of Continuing Medical Education in the Department of Medicine at Mount Sinai School of Medicine, New York, NY.
He has a triple appointment in the divisions of Liver Disease, Gastroenterology, and Infectious Diseases.
Douglas T. Dieterich graduated from Yale University in New Haven, CT and received his Doctorate of Medicine from New York University of Medicine in NY. He completed his internship and residency in Internal Medicine at the Bellevue Hospital Center in New York, NY where he was also a fellow in the Division of Gastroenterology. He became Clinical Assistant Professor of medicine and then a Clinical Professor of Medicine, both at the New York University. He remains as an Adjunct Clinical Professor of Medicine at New York University School of Medicine.
Dr. Dieterich is an investigator for many ongoing clinical trials evaluating the safety and efficacy of new antiviral treatments for chronic hepatitis B & C.
Dr. Dieterich is a member of many professional societies and is a fellow of both the American College of Physicians and the American College of Gastroenterology. He has served on several committees of the AIDS Clinical Trials Group at the National Institutes of Health (NIH), including the Steering Committee of the Opportunistic Infections Core Committee and the Cytomegalovirus (CMV) Committee. He was Chair and Co-Chair, respectively, of the Enteric Parasites Committee and the Protozoan Committee. He also served on the NIH Study Sections for CMV and cryptosporidiosis.
Widely published, Dr. Dieterich is the author of numerous journal articles, abstracts and book chapters on viral hepatitis and AIDS associated infections of the gastrointestinal tract and liver.
In the News
Dr. Dieterich discusses viral hepatitis in The Daily News feature The Daily Check Up.
View the PDF
Dr. Dieterich discusses the advancements in the treatment of Hepatitis C in The Daily News Feature, The Daily Check Up.
Dieterich DT. Treatment of Hepatitis C and Anemia in Human Immunodeficiency Virus-Infected Patients. J Infect Dis 2002; 185(suppl 2): S128-S137.
Soriano V, Sulkowski M, Bergin C, Hatzakis A, Cacoub P, Katlama C, Cargnel A, Mauss S, Dieterich D, Moreno S, Ferrari C, Poynard T, Rockstroh J. Care of Patients with Chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. AIDS 2002; 16: 813-828.
Palmon R, Koo BC, Shoultz DA, Dieterich DT D. Lack of Hepatotoxicity Associated with Nonnucleoside Reverse Transcriptase Inhibitors. J Acquir Immune Defic Syndr 2002; 29: 340-345.
Dieterich DT. Human Immunodeficiency Virus and the Liver: Lessons Learned and Still be Learned. Seminars in Liver Disease 2003; 23(2): 107-114.
Dieterich DT. HIV and Hepatitis B Virus: Options for Managing Coinfection. Topics in HIV Medicine 2003; 11(1): 16-19.
Nickolas K, Dieterich DT. Toxicity of Non-Nucleoside Analogue Reverse Transcriptase Inhibitors . Seminars in Liver Disease 2003; 23(2): 173-182.
Dieterich DT. Managing Antiretroviral-Associated Liver Disease . Journal of Acquired Immune Deficiency Syndromes; 22.
- Antiviral Effect, Safety, & Pharmacokinetics of once Daily BI 201335 NA in Hepatitis C Virus Genotype 1 Infected Treatment-Naive Patients for 24 weeks as Combination Therapy with Pegylated Interferon-a 2a and Ribavirin
- Multiple Rising Oral Doses of BI 201335 NA for Hepatitis
- Comparative Study of Hepatitis B Pts:The BE-LOW Study
- Telaprevir (VX-950) Pegasys & Copegus in Hepatitis C
- A Randomized Study of Stopping Treatment at 24 Weeks or Continuing Treatment to 48 Weeks in Treatment -Naive Subjects with Genotype 1 Chronic Hepatitis C who Achieve an Extended Rapid Viral Response (eRVR) while Receiving Telaprevir, Peginterferon Alfa2a (Pegasys) and Ribavirin (Copegus) [VX08-950-111]
- 2 Dose Regimens of Telaprevir in Comb. w/Pegasys&Copegus
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Dieterich during 2014 and/or 2015. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
- AbbVie Inc.; Boehringer Ingelheim Corporation; Bristol-Myers Squibb; Gilead Sciences, Inc.; Idenix Pharmaceuticals; Janssen Scientific Affairs, LLC; Merck & Co., Inc.; Novartis / Genentech Inc. Partnership; Quintiles; Roche Molecular Systems Inc.; Tobira Therapeutics, Inc.; Vertex Pharmaceuticals Incorporated
Industry-Sponsored Lectures: MSSM faculty occasionally give lectures at events sponsored by industry, but only if the events are free of any marketing purpose.
- Gilead Sciences, Inc.; Merck & Co., Inc.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
Annenberg Building Floor 21st Floor Room Room 21-42
1468 Madison Avenue
New York, NY 10029
5 East 98th Street
New York, NY 10029
- Tuesday 8:00am - 4:00pm
- Thursday 8:00am - 4:00pm
- Friday 8:00am - 12:00pm
- 1199 Member Choice
- Aetna POS
- Aetna PPO
- Aetna U.S. Healthcare - HMO
- BCBS Child Health Plus
- BCBS Direct HMO
- BCBS Direct POS
- BCBS Direct Pay HMO
- BCBS Direct Pay HMO/POS
- BCBS EPO
- BCBS Empire Prism EPO
- BCBS Empire Prism PPO
- BCBS HMO
- BCBS Health New York
- BCBS MediBlue HMO
- BCBS MediBlue PPO
- BCBS PPO
- Beech Street
- CIGNA Healthcare HMO
- Choice Care
- Cigna - PPO
- Cigna EPO
- Cigna POS
- Devon Health Services
- Group Health Insurance (GHI) - HMO
- Group Health Insurance (GHI) - PPO
- HIP Commercial
- HIP Medicaid
- HIP Medicare
- Island Group
- MedCare International
- Medicaid New Jersey
- Oxford Freedom
- Oxford Liberty
- Travel Care Services
- United Health Care - Mount Sinai Top Tier
- United Health Care Commercial
- United Health Care Empire Plan
- Master Card
- American Express
- Personal Check